Skip to main content
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. — Investor Relations & Filings

Ticker · SGMT ISIN · US7867001049 LEI · 2549002OT2F8BV0VPD02 US Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2026-02-12 Director's Dealing
Country US United States of America
Listing US SGMT

About Sagimet Biosciences Inc.

https://sagimet.com/

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company that develops novel fatty acid synthase (FASN) inhibitors. These therapeutics are designed to target dysfunctional metabolic and fibrotic pathways resulting from the overproduction of the fatty acid, palmitate. The company's lead product candidate is denifanstat, and its pipeline includes TVB-3567. Sagimet is exploring the application of its FASN inhibitors in treating diseases where dysregulation of fatty acid metabolism plays a key role, such as metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2026-02-12 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or disclosures that shareholders should know about between periodic reports. The text includes a Regulation FD Disclosure about a press release and an updated investor presentation, both attached as exhibits. The document explicitly states that the press release and presentation are furnished and not filed, indicating this is a current report rather than a full financial report or earnings release. The presence of an investor presentation as an exhibit and the nature of the disclosure about clinical trial results and investor meetings strongly suggest this is a Capital/Financing Update or similar event disclosure. However, since the document is a Form 8-K with Regulation FD Disclosure and includes an investor presentation update, the best fitting category is Capital/Financing Update (CAP). The document is not an earnings release (ER) because it does not present financial results, nor is it an investor presentation (IP) alone because it is part of a Form 8-K filing. Confidence is high due to clear identification of the form and content.
2026-02-02 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-12-18 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Sagimet Biosciences Inc. It includes an updated investor presentation (Exhibit 99.1) and a press release (Exhibit 99.2) announcing positive Phase 1 trial results. The text explicitly states that the presentation is being furnished and not filed, and the document is a current report rather than a full financial report. The presence of an investor presentation as an exhibit and the nature of the content (updates for investors) strongly indicate this is an Investor Presentation filing. The document length is 4699 characters, which is consistent with a Form 8-K filing containing an investor presentation and press release, not a full annual or quarterly report. Therefore, the classification is Investor Presentation (IP).
2025-12-18 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content describes a license agreement entered into by Sagimet Biosciences Inc. with another company, including financial terms and contractual details. There is no detailed financial data or comprehensive report content such as an annual or quarterly report. The document includes a press release as an exhibit and is signed by the CEO. This type of filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement of a material event and does not fit into more specific categories like earnings release or capital update. The document length is under 5,000 characters, consistent with a brief announcement rather than a full report.
2025-12-17 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-11-22 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.